Search results
Results From The WOW.Com Content Network
Mr. Justice Aftab Alam [ 1] Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the ...
Bimagrumab ( BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. It binds to and inhibits activin receptor type-2B. [ 1] Bimagrumab must be administered intravenously at a hospital or clinic. The medication has a long half life and is administered once a month.
Pfizer: Off-label promotion of Bextra, Geodon, Zyvox and Lyrica, September 2009. In what was the largest pharmaceutical settlement in U.S. history at the time, Pfizer reached a $2.3 billion settlement with the Department of Justice to resolve criminal charges and civil claims under the False Claims Act.
Novartis and Viatris were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and ...
ROME (Reuters) -Italy's antitrust regulator said on Thursday it had launched an investigation into pharmaceutical companies including Novartis and Roche-controlled Genentech for having potentially ...
By Chelsea Emery Never mind coal. There may be pink slips in some holiday stockings this year. The end of the year can be a dangerous season for employees. As companies make last-minute attempts ...
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until ...
It is Novartis' proprietary adjuvant that is added to influenza vaccines to help stimulate the human body's immune response through production of CD4 memory cells. [1] [2] [3] MF59 is the first oil-in-water influenza vaccine adjuvant to be commercialized in combination with a seasonal influenza virus vaccine.